Domain Therapeutics has announced a rebrand to Kainova Therapeutics.
The rebrand is to reflect the company’s clinical momentum, global focus and readiness for the next chapter of strategic growth, anchored by a mature pipeline of G Protein-Coupled Receptor (GPCR)-modulating therapies.
The name “Kainova” combines “Kairos,” the opportune or decisive moment and “Nova,” symbolising innovation and renewal.
It embodies the company’s transformation and ambition, reflecting its drive to innovate, determination to deliver and commitment to therapies that truly transform lives.
Built on a strong scientific foundation, a proprietary discovery platform, an integrated development approach and experienced leadership, the new brand underscores Kainova’s commitment to clinical excellence, value creation and lasting impact.
"The rebrand is not a break from our scientific or strategic roots," said Sean MacDonald, CEO of Kainova Therapeutics.
"It is the clearer expression of who we are today and the impact we strive to deliver for patients."
"It highlights a continuation between our past successes and the growth path we envision for the future. Above all, Kainova Therapeutics embodies our belief that better is always possible."
Leveraging decades of scientific and medical expertise and a proven track record of collaborations with pharma, Kainova is advancing innovative, clinically differentiated therapies designed to unlock the untapped potential of GPCRs.
The company’s leading programmes include the following:
- DT-7012, a Treg-depleting anti-CCR8 antibody with competitive properties in Phase I/II trials for solid tumours
- DT-9046, a first-in-modality, pre-IND biased PAR2 antagonist in inflammation
- and DT-9081, a Phase II-ready EP4 receptor antagonist for solid tumours.
With operations in North America, France and Australia, plus a growing clinical pipeline, Kainova is entering its next chapter, shaping the future of GPCR-modulating therapies, transforming lives and expanding its global reach.
The Kainova leadership will be in San Francisco during the J.P. Morgan Healthcare Conference, January 12-15, 2026 and welcomes the opportunity to share how the company is advancing its clinical pipeline of GPCR-modulating therapies to create a meaningful impact for patients.